Tumor-specific mAbs are one of the stimuli inducing ADCC medicated by NK cells in immunotherapies in CLL, which recognize the different ligands on the surface of CLL cells, including CD20, CD19 and CD37 (17, 56). This evidence concerns the gene CD19 and B-cell chronic lymphocytic leukemia.